Abstract

The tumor microenvironment (TME) plays a pivotal role in cancer progression, therapeutic resistance, and 
metastasis. Characterized by hypoxia, acidic pH, and a dense extracellular matrix (ECM), the TME creates a 
unique niche that conventional therapies struggle to penetrate. Nanomedicine has emerged as a promising 
platform to overcome these barriers by designing smart, stimuli-responsive drug delivery systems that 
selectively respond to TME-specific cues. This review provides a comprehensive overview of tumor 
microenvironment-responsive nanomedicines, with a focus on their ability to exploit hypoxia, acidity, and ECM 
abnormalities for targeted and controlled drug release. We explore the design principles, recent advances, and 
therapeutic benefits of such systems, highlighting their role in enhancing drug bioavailability, minimizing off
target toxicity, and improving clinical outcomes. Furthermore, we discuss translational challenges and future 
directions to realize the full potential of these nanocarriers in personalized cancer therapy.